On this page · 5 sections→
Where the EU money came from
Funding by EU programme. Amounts are Remab Therapeutics SL's own share of each project, not the project's full budget.
- Horizon Europe€3.3M · 1 project
- Horizon 2020€50k · 1 project
Projects
2 EU-funded projects, newest first. Remab Therapeutics SL led 2 of them as coordinator. Each links to the official record.
- DITRAPCoordinator
Disarming the Immune TRAP through a Targeted Antibody Removal Therapy to Prevent ICU-Acquired Infections and Reduce Antimicrobial Resistance
Horizon Europe · 2026–2030 · Project on CORDIS ↗
€3.3Mtheir share - HAIKUCoordinator
A breakthrough alternative to antibiotics for preventing and curing infectious diseases at Intensive Care Units
Horizon 2020 · 2018–2019 · Project on CORDIS ↗
€50ktheir share
Works most with
Organisations that shared the most EU projects with this one. A good starting list for consortium partners.
Fields it works in
Research fields recorded on its Horizon projects.
- anaesthesiology
- antibiotic resistance
- antibiotics
- critical care medicine
- infectious diseases
- multidrug resistance
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.